Lenvatinib, sold under the brand name Lenvima among others, is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases. |
Read full article at Wikipedia
|
InChI=1S/C45H93N2O6P/c1- 6- 8- 10- 12- 14- 16- 18- 20- 21- 22- 23- 24- 25- 27- 29- 31- 33- 35- 37- 39- 45(49) 46- 43(42- 53- 54(50,51) 52- 41- 40- 47(3,4) 5) 44(48) 38- 36- 34- 32- 30- 28- 26- 19- 17- 15- 13- 11- 9- 7- 2/h43- 44,48H,6- 42H2,1- 5H3,(H- ,46,49,50,51) /t43- ,44+/m0/s1 |
FONAXCRWZQFJHY-JCGOJSMZSA-N |
CCCCCCCCCCCCCCC[C@H]([C@H](COP(=O)([O-])OCC[N+](C)(C)C)NC(CCCCCCCCCCCCCCCCCCCCC)=O)O |
|
(2-{[(2S,3R)-2-docosanamido-3-hydroxyoctadecyl phosphonato]oxy}ethyl)trimethylazanium
|
N-(Docosanoyl)-sphinganine-1-phosphocholine
|
HMDB
|
Sphingomyelin
|
HMDB
|
Sphingomyelin (d18:0/22:0)
|
HMDB
|
20671299
|
PubMed citation
|
Europe PMC
|
|